

Trieste, 29th January 2024

Dear respected Editors and Reviewer,

We submit the revised version of our editorial manuscript (Ms No.: 91754) entitled "Hepatitis B virus genotypes in precision medicine of hepatitis B-related hepatocellular carcinoma: Where we are now" for publication in the World Journal of Gastrointestinal Oncology.

We thank the overall positive comments of the Reviewer and the Editors.

In response to the letter from the editorial office, we revised the previous version and prepared a point-by-point answer (As) that addresses the Queries (Qs) by the reviewer and the editors. The revised Ms includes the text with track changes containing revisions based on the previous version and highlighted in yellow as requested by editors.

We hope to have comprehensively revised the Ms, which further helped to improve the quality of the Ms and we expect this may be now officially accepted for publication.

On behalf of all the co-authors, I thank you for your attention and send you our best regards.

Sincerely,



Caecilia H. C. Sukowati, Ph.D

Senior Scientist

Liver Cancer Unit

Fondazione Italiana Fegato ONLUS,

AREA Science Park, Basovizza, 34049 Trieste, Italy

caecilia.sukowati@fegato.it

REVIEWER COMMENTS

Reviewer #1

Scientific Quality: Grade B (Very good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Accept (General priority)

Specific Comments to Authors:

Q1: The authors have written an comprehensive editorial regarding HBV genetic diversity and HCC and have summarized the genetic diversity of HBV regarding the progression to HCC. Generally the manuscript is well written but there are some minor grammatical errors that should be corrected

A1: We thank the Reviewer for the comments. The grammatical errors have been corrected. The changes in the manuscript can be followed by the track changes which are highlighted in yellow.

EDITORIAL OFFICE'S COMMENTS

1. Science Editor

Q1 Manuscript's theme: The topic is within the scope of the journal.

A1: We thank the Editor for the comment.

Q2 Scientific quality: The author submitted an editorial on hepatitis B virus genotypes in precision medicine for hepatitis B-related hepatocellular carcinoma. The manuscript is overall qualified.

(1) Advantages and disadvantages: The reviewers have given positive peer-review reports for the manuscript. Classification: Grade B; Language Quality: Grade B. The authors have written a comprehensive editorial. HBV genetic diversity and HCC and have summarized the genetic diversity of HBV regarding the progression to HCC. Generally the manuscript is well written but there are some minor grammatical errors that should be corrected.

(2) Main manuscript content: The author clearly stated the purpose of the study and the research structure is complete. However, the manuscript still require a further revision according to the detailed comments listed below.

(3) Table(s) and figure(s): There is no Figure and Table should be improved.

(4) References: A total of 48 references are cited, including 17 published in the last 3 years. The reviewer didn't request the authors to cite improper references published by him/herself.

A2: We thank the Editor for the comments. The grammatical errors have been corrected. The changes in the manuscript can be followed by the track changes and are highlighted in yellow.

Q3 Language evaluation: The English-language grammatical presentation needs to be improved to a certain extent. There are many errors in grammar and format, throughout the entire manuscript. Before final acceptance, the authors must provide the English Language Certificate issued by a professional English language editing company. Please visit the following website for the professional English language editing companies we recommend: <https://www.wjnet.com/bpg/gerinfo/240>.

A3: [The grammatical errors have been corrected. The language certificate have been provided \(please see attached documents\)](#) *Please Caecil to put the language certificate as we discussed. Thank you*

Q4 Specific comments:

(1) Please provide the filled conflict-of-interest disclosure form.

(2) Please upload the approved grant application form(s) or funding agency copy of any approval document(s).

A4: [We have provided the conflict-of-interest disclosure form \(please see attached documents\). The grant application form is not applicable.](#) *Please Caecil to check the required document. Thank you*

2. Company editor-in-chief comments

Q1: I have reviewed the Peer-Review Report, and full text of the manuscript, all of which have met the basic publishing requirements of the World Journal of Gastrointestinal Oncology, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors.

When revising the manuscript, it is recommended that the author supplement and improve the highlights of the latest cutting-edge research results, thereby further improving the content of the manuscript. To this end, authors are advised to apply PubMed, or a new tool, the RCA, of which data source is PubMed. RCA is a unique artificial intelligence system for citation index evaluation of medical science and life science literature. In it, upon obtaining search results from the keywords entered by the author, "Impact Index Per Article" under "Ranked by" should be selected to find the latest highlight articles, which can then be used to further improve an article under preparation/peer-review/revision. Please visit our RCA database for more information at: <https://www.referencecitationanalysis.com/>, or visit PubMed at: <https://pubmed.ncbi.nlm.nih.gov/>.

A2: We thank the Company Editor-in-Chief comments. We have checked the references and all are listed and indexed in the RCA database.